Literature DB >> 7712441

Preoperative regional therapy for extremity sarcoma. A tricenter update.

H J Wanebo1, W J Temple, M B Popp, W Constable, B Aron, S L Cunningham.   

Abstract

BACKGROUND: Preoperative radiation with sensitizing doxorubicin has been popularized in the treatment of high grade sarcoma of the extremity. A multiinstitutional experience with this protocol that was initiated by the Southeastern Cancer Study Group in 1984 and maintained in three institutions was updated by the authors.
METHODS: Patients with biopsied sarcoma had intraarterial infusion with doxorubicin hydrochloride (Adriamycin) 30 mg/24 hrs x 3 days and were allocated by the institution to receive radiation 30-35 Gy in 10 fractions or 46 Gy in 23-25 fractions followed by resection. Surgery was performed within 10 days or 30 days depending on the radiation dose. Postoperative chemotherapy was administered to 31 patients.
RESULTS: Of 66 patients, 32 were female and 34 were male. The median age was 46 years (range, 14-77 years); 73% had lower and 27% had upper extremity tumors. There were 55 soft-tissue and 9 malignant bone tumors. Common types were malignant fibrous histiocytoma 20%; liposarcoma, 17%; synovial sarcoma 18%; and 14% were osteosarcoma. American Joint Committee on Cancer stages were: I, IIB (17%), IIIA/B (59%), and IIIC/4A (24%). Limb salvage surgery was performed on 60 patients including radical resection in 21 with extensive tumors, wide local excision in 30, and limited excision in 2 patients. Primary amputation was performed on four patients and delayed amputation in two because of wound complications. Three patients had pulmonary metastasectomy in conjunction with primary surgery (2 are long term survivors > 5 years). There were no postoperative deaths, but wound complications occurred in 41% of the patients. Overall survival and disease free survival at 5 years was 59 and 49%. One patient (1.5%) had local recurrence 9 years after resection of an extensive synovial sarcoma of the shoulder. This was resected with limb salvage techniques. Among 23 patients who failed primarily in the lung, the median survival was 7 months with 4 surviving more than 5 years, after demonstration of the pulmonary metastases. Multivariant analysis of prognostic factors showed that extent of disease and stage correlated with disease free survival, whereas only extent of surgical resection correlated with overall surgical survival.
CONCLUSION: Combined therapy for extremity sarcoma in a multicenter setting using preoperative radiation with sensitizing chemotherapy and adequate resection was associated with an excellent local control rate (98.5%) and reasonable long term tumor control, although distant metastases continued to be a major challenge.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7712441     DOI: 10.1002/1097-0142(19950501)75:9<2299::aid-cncr2820750919>3.0.co;2-y

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  11 in total

Review 1.  Management of infection following reconstruction in bone tumors.

Authors:  Sudhir K Kapoor; Rajesh Thiyam
Journal:  J Clin Orthop Trauma       Date:  2015-07-07

Review 2.  Preoperative therapy for extremity soft tissue sarcomas.

Authors:  Lara E Davis; Christopher W Ryan
Journal:  Curr Treat Options Oncol       Date:  2015-06

3.  [Consensus diagnosis and therapy of soft tissue sarcoma].

Authors:  Thomas Brodowicz; Gabriele Amann; Andreas Leithner; Arpad Sztankay; Franz Kainberger; Wolfgang Eisterer; Bernadette Liegl-Atzwanger; Franz Rachbauer; Thomas Rath; Michael Bergmann; Philipp T Funovics; Ferdinand Ploner; Reinhard Windhager
Journal:  Wien Klin Wochenschr       Date:  2011-10-28       Impact factor: 1.704

4.  Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience.

Authors:  A M Eggermont; H Schraffordt Koops; J M Klausner; B B Kroon; P M Schlag; D Liénard; A N van Geel; H J Hoekstra; I Meller; O E Nieweg; C Kettelhack; G Ben-Ari; J C Pector; F J Lejeune
Journal:  Ann Surg       Date:  1996-12       Impact factor: 12.969

5.  Pathologic femur fractures after limb-sparing treatment of soft-tissue sarcomas.

Authors:  Anne H Blaes; Bruce Lindgren; Daniel A Mulrooney; Lauren Willson; L Chinsoo Cho
Journal:  J Cancer Surviv       Date:  2010-09-09       Impact factor: 4.442

6.  A non-comparative phase II study of dose intensive chemotherapy with doxorubicin and ifosfamide followed by high dose ICE consolidation with PBSCT in non-resectable, high grade, adult type soft tissue sarcomas.

Authors:  Jörg Thomas Hartmann; M Horger; T Kluba; A Königsrainer; P de Zwart; C Hann von Weyhern; F Eckert; W Budach; C Bokemeyer
Journal:  Invest New Drugs       Date:  2013-10-04       Impact factor: 3.850

7.  Primary tumor necrosis predicts distant control in locally advanced soft-tissue sarcomas after preoperative concurrent chemoradiotherapy.

Authors:  Dhara M MacDermed; Luke L Miller; Terrance D Peabody; Michael A Simon; Hue H Luu; Rex C Haydon; Anthony G Montag; Samir D Undevia; Philip P Connell
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-07-04       Impact factor: 7.038

Review 8.  Optimizing radiation therapy and post-treatment function in the management of extremity soft tissue sarcoma.

Authors:  Thomas F DeLaney
Journal:  Curr Treat Options Oncol       Date:  2004-12

9.  Neoadjuvant chemoradiation compared to neoadjuvant radiation alone and surgery alone for Stage II and III soft tissue sarcoma of the extremities.

Authors:  Kelly K Curtis; Jonathan B Ashman; Christopher P Beauchamp; Adam J Schwartz; Matthew D Callister; Amylou C Dueck; Leonard L Gunderson; Tom R Fitch
Journal:  Radiat Oncol       Date:  2011-08-09       Impact factor: 3.481

10.  High incidence of metastatic disease in primary high grade and large extremity soft tissue sarcomas treated without chemotherapy.

Authors:  Benedikt Leidinger; Thomas Heyse; Andreas Schuck; Horst Buerger; Philipp Mommsen; Thomas Bruening; Susanne Fuchs; Georg Gosheger
Journal:  BMC Cancer       Date:  2006-06-18       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.